Most Promising Applications of Artificial Intelligence (AI) in Healthcare Segment

Rare Diseases

Navigating the Healthcare Horizon: A January 20...

As we step into the crisp corridors of January 2024, the healthcare landscape unfolds a compelling saga of mergers, strategic funding, and transformative acquisitions. In this month's analysis, we ...

Feb 07, 2024

mrna-based-vaccines-and-therapeutics
Unleashing the Power of mRNA: A Revolutionary Approach to Vaccines and Therapeutics

The progress of mRNA-based therapeutics involves several key stages, including mRNA design, synthesis, entrapment, pharmacodynamics, pharmacokinetics, in vivo and in vitro safety evaluation, manufacturing, and clinical trials. Among these stages, mRNA design and synthesis play pivotal roles in developing mRNA-based...

Find More
voydeya-for-pnh-treatment
AstraZeneca Strengthens Presence in PNH Treatment with Voydeya in Japan: World’s First Approval

A month following Novartis’ foray into the paroxysmal nocturnal hemoglobinuria (PNH) treatment domain, AstraZeneca strengthens its position in this field as its latest contender, Voydeya, secures a groundbreaking approval in Japan. Voydeya (danicopan), an innovative oral factor D inhibitor, has received approval fr...

Find More
A Glance at Key Insights From 42nd J.P. Morgan Annual Healthcare Conclave

From January 8th to 11th, 2024, the 42nd Annual J.P. Morgan Healthcare Conference (JPM24) took center stage in San Francisco, CA, USA. Spanning four dynamic days, this conference saw the active participation of prominent figures from major pharmaceutical, biotechnology, Medtech, HealthTech entities, and emerging fa...

Find More

More Views & Analysis

Pharma News for Merck, AbbVie, Abbisko
Merck to Acquire Harpoon Therapeutics; Novo Nordisk Enters Into Collaborations with Omega Therapeutics and Cellarity; AbbVie’s Lutikizumab’s Phase II Trial Result for Hidradenitis Suppurativa; Abbisko’s CSF-1R Inhibitor Pimicotinib (ABSK021); Cabaletta Bio’s CABA-201; FDA Grants Fast Track” Designation for Soligenix’s Dusquetide

Lutikizumab Showed Positive Results in a Phase II Trial of Adults with Moderate to Severe Hidradenitis Suppurativa as Program Advances to Phase III AbbVie has reported the results of Phase II trials indicating that adults experiencing moderate to severe hidradenitis suppurativa, and who had previously not respon...

Find More

wainua-for-hattr-pn-treatment
Wainua – The Only Approved Medicine for hATTR-PN Treatment

Ionis Pharmaceuticals and AstraZeneca concluded the year 2023 on a positive note as they received the eagerly awaited approval from the FDA for their transthyretin amyloidosis (ATTR) medication, Wainua. In particular, the agency approved the use of the ligand-conjugated antisense oligonucleotide (LICA) medication f...

Find More

expanding-market-of-complement-inhibitor
The Expanding Market of Complement Inhibitors

The development of complement inhibitors has been growing rapidly over the years, and it has proved to be one of the breakthroughs in various therapeutic areas. These inhibitors act on the dysregulated complement system, a group of proteins that forms an essential part of innate immunity. This system comes into eff...

Find More

lyfgenia-or-casgevy-for-sickle-cell-disease-treatment
Lyfgenia or Casgevy: Who Will Lead the Sickle Cell Disease Treatment Space?

History has been created as the world captures the significance of the FDA’s approval of Casgevy (exa-cel), a collaboration between Vertex Pharmaceuticals and CRISPR Therapeutics, for the treatment of sickle cell disease (SCD). This groundbreaking therapy represents a long-awaited potential cure for the debilitatin...

Find More

Pharma News for AskBio, Almirall, Bayer, Pfizer
Key Updates on Phase 1 Trial of AB-1005 Gene Therapy for Multiple System Atrophy-Parkinsonian Type; European Commission Approves EBGLYSS; Bayer Stopped OCEANIC-AF Study; Pfizer and Astellas’ XTANDI Approved by FDA; FDA Orphan Drug Designation to Epic Bio’s EPI-321; FDA Fast Track Designation to Chemomab’s CM-101 for PSC

AskBio Announces First Patient Randomized in Phase 1 Trial of AB-1005 Gene Therapy for Multiple System Atrophy-Parkinsonian Type Asklepios BioPharmaceutical, Inc., a gene therapy firm fully owned and independently operated under Bayer AG, announced the initiation of the Phase I REGENERATE MSA-101 clinical trial ...

Find More

tibsovo-for-myelodysplastic-syndrome-treatment
Servier’s Tibsovo Opens The Door To A New Era In The Battle Against Myelodysplastic Syndromes

Servier’s Tibsovo (ivosidenib tablets) has received an expanded indication from the FDA, allowing its utilization in patients diagnosed with relapsed or refractory myelodysplastic syndromes that exhibit an IDH1 mutation. This new approval represents the fifth for Tibsovo, which is already recognized for its efficac...

Find More

Cachexia is a complicated metabolic syndrome related to underlying illness and characterized by musc.....

Find More

Osteosarcoma is a kind of bone cancer that originates from the cells that form bones. It is often fo.....

Find More

An inflammatory disease of large intestine, Ulcerative Colitis (UC), is approached with therapies th.....

Find More

Cancer, an immunologic condition that can begin in any organ or tissue of the body is the second lea.....

Find More

Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease that results in systemic inflamma.....

Find More

Axial Spondyloarthritis (axSpA) is an umbrella term for a form of inflammatory form of arthritis ass.....

Find More